Bladder Cancer | Unmet Need | US/EU | UNNEON0011-2017
Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However, following the 2016-2017 FDA approvals of the PD-L1 inhibitor Tecentriq (Roche/Genentech) and the PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.
Questions Answered:
- What are the treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
- What are the prevailing areas of unmet need and opportunity in unresectable locally advanced or metastatic bladder cancer?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for unresectable locally advanced or metastatic bladder cancer?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017
Key companies: Bristol-Myers Squibb, Eli Lilly, Roche/Genentech
Key drugs: Tecentriq, Javlor, gemcitabine
